HRMY After Earnings: Shorts Ease but Bears Haven't Left

Harmony Biosciences has just printed Q3 results, and the positioning data tells a story of bears who built aggressively into the number and are now only partially unwinding.

Short interest came into the print at close to 10% of the free float, the product of a deliberate 21% month-on-month build that began in early October. Since the November 4 release, the short position has ticked fractionally lower, from a recent peak near 5.77 million shares to 5.74 million. That is not a meaningful cover. Bears who added through October are largely still there, even after the stock fell 2.3% on the day and 2.5% on the week to close at $37.02. The options market, which had been flashing its most defensive read of the year heading into earnings with a put/call ratio near its 52-week high of 2.93, has barely moved. The PCR printed at 2.88 on November 3, still well above its 20-day average of 2.47. Downside hedging remains elevated even after the event has passed. Borrow conditions continue to impose no discipline on the bears: availability is roughly 441%, meaning shares available to lend are more than four times current short interest, and the cost to borrow is just 0.48%. Shorts can hold or add cheaply.

The Street's view is notably more constructive than the positioning suggests, which is the central tension in this note. The analyst consensus sits solidly bullish, with Needham and HC Wainwright holding Buy ratings and targets of $50 and $55 respectively, both reiterated in October. Wolfe Research initiated at Outperform with a $60 target in August. The mean price target is $48.08, implying roughly 30% upside from the current $37.02 print. Truist and Deutsche Bank both hold Hold ratings but raised targets to $34 and $36 in the summer, acknowledging the improving trajectory even from the sidelines. On value, the stock trades at a PE of 5.5x and EV/EBITDA of 4.5x, both compressing alongside the share price over the past month. The earnings yield factor ranks in the 91st percentile, and forward EPS estimates continue to rise, with the 12-month forward growth rank at the top of the universe. The factor picture looks attractive on paper; the market is not paying for it.

The bull and bear cases both hinge on WAKIX. Bulls note that 2026 net revenue guidance was reaffirmed at $1.00 billion to $1.04 billion, against a FactSet consensus of $1.03 billion, with roughly 8,950 average patients on therapy and a cash balance of $962.5 million. The pipeline includes pitolisant in additional indications, BP-205, Zygel, and EPX-100. The CEO transition to Peter Anastasiou on January 1, 2027, with current CEO Jeffrey Dayno advising through the year, has been framed as orderly. Bears counter that WAKIX faces sodium oxybate competition and potential earlier-than-expected generic pitolisant entry, with no single pipeline asset large enough to replace the core franchise if adoption slows or litigation goes badly. The concentrated single-product risk is the reason a stock trading at 5.5x earnings carries 10% short interest.

One incremental data point worth noting: ORTEX Alt Data tracks Medicaid reimbursements for Harmony's drugs via Centers for Medicare & Medicaid Services data. Medicaid dollars reimbursed have risen for four consecutive quarters, with the Q1 2026 reading of $38.7 million running 20% above the same quarter a year earlier. This dataset has not been measured as a leading indicator for Harmony's reported financials, so it describes the Medicaid channel only and carries no implication for the print. It does confirm that payer-channel demand was not collapsing through early 2026.

On ownership, BlackRock filed a 13G/A on October 27 showing its stake at 12.6% of shares, up from a prior 11.3%, adding roughly 539,000 shares in the quarter to September 30. American Century and Dimensional also added meaningfully in Q3. Antonio Gracias, once an 11.7% holder, has reduced to 3.2% per his most recent filing. The insider data is less fresh: the most recent Form 4 activity on record dates to mid-September, when the CMO exercised options and sold shares in the open market, a net seller across those transactions. No open-market purchases from directors or officers appear in the recent record.

The next earnings event is not until February 23, 2027, leaving a long runway before another binary catalyst. The question for the coming weeks is whether the short position that survived the Q3 print intact begins to unwind as the stock re-rates toward analyst targets, or whether bears use the loose borrow market to add further if management guidance or pipeline updates disappoint at upcoming conferences.